Acute Rheumatic Fever
Definition

• Acute rheumatic fever is a systemic inflammatory disease occurring as a sequel to β-haemolytic streptococcal infection with clinical manifestation of the response.

• Its severity in an individual is determined by host genetic susceptibility, the virulence of the infecting pathogen and a conducive environment.
Acute Rheumatic Fever

• The clinical presentation can be vague and difficult to diagnose.
• Currently the modified Jones criteria form the basis of the diagnosis of the condition.
• Autoimmune consequence of infection with Group A streptococcal infection
• Results in a generalised inflammatory response affecting brain, joints, skin, subcutaneous tissues and the heart.
Epidemiology

- Usually 5 – 18 yrs old.
- M:F equally except Sydenham’s chorea which is more common in girls.
- As many as 20 million new cases occur each year.
- The introduction of antibiotics has been associated with a rapid worldwide decline in the incidence of ARF.
- Now, the incidence is 0.23-1.88 patients per 100,000 population.
- From 1862-1962, the incidence declined from 250 patients to 100 patients per 100,000 population, primarily in teenagers.
2005 Estimated Global Burden
(new cases per year in 5-14 year olds)

- Acute RF no carditis: 188,000
- Acute RF with RHD: 282,000
- GAS Pharyngitis: 616,000,000

Total: 471,000

Rheumatic Heart Disease

• Rheumatic Heart Disease is the permanent heart valve damage resulting from one or more attacks of ARF.

• It is thought that 40-60% of patients with ARF will go on to developing RHD.
ARF: Etiology

• gr. A β-haemolitic Streptococcus (type 12 and 49)
• Bacteria populates the superior respiratory tract and acts via a series of toxic products, as well as: erithrogenic toxin important in pathogenesis of scarlet fever, streptolysine S, streptolysine O, streptokynase (fibrinolisyne), streptodornase (deoxyribonuclease), NAD-ase (nycotid-adenyl-dinucleotydase), hyaluronidase.
β-haemolitic Streptococcus

• Encapsulated gram-positive bacteria
• Protein M: anti-phagocytic \(\text{(most important virulent factor)}\)
• Lipoteichoic acid: colonization
• Extracellular factors:
  • Streptolisine O
  • Deoxyribonuclease B
  • Hyaluronidase

  Against them during first days of acute infection antibodies are produced

• Erithrogenic Toxins / Pyrogenic \(\text{(alter T-cells function, cause endo-toxic shock)}\)
Wall structure of GAS

Figure 11-13
A schematic representation of the group A streptococcal cell wall.
β-haemolitic Streptococcus

• Found in pharynx of children 6-9 years x2 times often than those aged 12-15, and x6 times than in adults.
• ARF has the maximal incidence during the cold period of the year – autumn after schools open, winter and spring, when the incidence of GAS infection is higher.
• ARF develops after a latent period of 2-6 weeks from streptococcal pharyngitis
Diseases caused by GAS

Superficial infections
- Pharyngitis
- Pyoderma

Invasive infections
- Sepsis
- Pneumonia, osteomyelitis, etc.
- Necrotizing fasciitis

Toxin mediated diseases
- Scarlet fever
- Syndrome of Streptococcic toxic shock
- Autoimmune post-streptococcic sequela
  - ARF/ CHD
  - Post-streptococcic glomerulonephritis
Acute Tonsillitis

- Swollen uvula
- White follicles on tonsils
Risk factors for ARF

• **Family history.** Some people may carry a gene or genes that make them more likely to develop rheumatic fever.

• **Type of strep bacteria.** Certain strains of strep bacteria are more likely to contribute to rheumatic fever than are other strains.

• **Environmental factors.** A greater risk of rheumatic fever is associated with overcrowding, poor sanitation and other conditions that may easily result in the rapid transmission or multiple exposures to strep bacteria.
Pathogenesis

Mechanisms – not clear elucidated;
Theories:
1. Infectious;
2. Toxic;
3. Autoimmune – most accepted.

The inflammation is a result of:
- a) Hyper-immune reactions against streptococcal Ag;
- b) Cross-reaction between antigen compounds of GAS and conjunctive tissue & myosin;
- c) Autoimmune aggression;
- d) Cellular immunity impairments & development of hypersensibilization state type IV.

ARF – a consequence of immunogen GAS infection and uncontrolled humoral and cellular immune response of host organism, in a person with a genetic predisposition.
Pathogenic characteristics of GAS

Adherence to epithelial cells:
>10 adhesion molecules

Invasion of epithelial cells:
mediated by M- and F-proteins
important for invading & persistence of GAS into epithelial tissue

Disturbance of opsonization & phagocytosis:
M-protein, M-like protein, C5a peptidase

Produce enzymes & toxins
Enzymes & toxins

**Streptokinase** (fybrinolizine)
May induce cellular lysis and is responsible for quick spread of streptococci.
Used (IV) for treatment of pulmonary embolism, coronary & venous thrombosis.

**Streptodornase** (DNA-se A-D)
Reduces viscosity of DNA suspension.

**Hyaluronidase** (factor of infection spread):
Alters conjunctive tissue and facilitates the spread of infection.

**C5a peptidase**
Blocks the phagocytosis of streptococci - important in survival of *S. pyogenes* in tissues and blood.
Initially, *infectious theory*, proposed during 1930s, assumed the persistence of Streptococci in conjunctive tissue, and, in fact, sustained that the disease is a form of infective endocarditis. Later this theory was declined, because no bacteria was found in tissue lesions.
Pathogenesis

In parallel the *toxic theory*, which stated that the capacity of Streptococci to eliminate some toxins and enzymes could induce lesions of different cells and tissue of host, and therefore to play a role in pathogenesis. Later was demonstrated that administration of isolated toxins does not cause the diseases.
Pathogenesis

The most accepted hypothesis nowadays are **immune** (explain inflammation via reaction Antigen – Antibody at conjunctive tissue) and **autoimmune** (inflammation is result of autoimmune reaction due to similarities between human and streptococcal antigens).

Streptococci & their toxins, acting in the host organism, induce developing of characteristic to rheumatism inflammatory process, and break of antistreptococcal humoral immunity.

ARF develops only in persons with an excessive immune response (hyper-sensibility) to streptococcus compounds.
Pathogenesis

• Streptococcal pharyngitis with GAS
• Production of *antibodies* against streptococci
• These Antibodies *cross-react with human tissues* due to *antigenic similarity* between compounds of streptococci and human conjunctive tissue (molecular mimicry)
• Immunologic mediated inflammation & lesions *(autoimmune)* of host tissues with antigenic similarity: heart, joints, brain…
Pathogenesis

✓ Group A strep pharyngeal infection precedes clinical manifestations of ARF by 2 - 6 weeks.
✓ Antibodies produced against group A strep cross-react with human tissue:
  • heart valve and brain share common antigenic sequences with GAS bacteria.
✓ Theory of molecular mimicry
✓ Host immune responses may play a role in determining who gets ARF following infection.
✓ Virulent strains: rheumatogenic serotypes.
Pathogenesis

- Delayed immune response to infection with group A beta hemolytic streptococci.
- After a latent period of 1-3 weeks, antibody induced immunological damages occur in heart valves, joints, subcutaneous tissue & basal ganglia of brain.
Pathogenesis

• Acute rheumatic fever is a hypersensitivity reaction classically attributed to antibodies directed against group A streptococcal molecules that also are cross-reactive with host antigens.
• In particular, antibodies against M proteins of certain streptococcal strains bind to proteins in the myocardium and cardiac valves and cause injury through the activation of complement and FC receptor-bearing cells (including macrophages).
• CD4+ T cells that recognize streptococcal peptides also can cross-react with host antigens & elicit cytokine-mediated inflammatory responses.
Antibodies are produced against M protein of streptococci

\[ \downarrow \]

Cross reaction with self-antigens of the heart

\[ \downarrow \]

Cytokine production

\[ \downarrow \]

Macrophage activation

\[ \downarrow \]

Damage to heart (by both antibody & cell-mediated reactions)
Group A β-Hemolytic Streptococcus

• Strains that produce rheumatic fever - M types 1, 3, 5, 6, 18 & 24

• Pharyngitis - produced by GABHS can lead to - acute rheumatic fever, rheumatic heart disease & post strept. Glomerulonephritis

• Skin infection - produced by GABHS leads to post streptococcal glomerulonephritis only. It will not result in ARF or carditis as skin cholesterol suppresses antigenicity
Genetic predisposition

After GAS infection only 0,3% in general population and 3% - of population during the epidemic GAS infection – develops ARF. A multifactorial type of heredity is involved in ARF:

1. A number of genes could cause a permanently maintenance of the disease, in contact with environmental factors.
2. There is shown an association of high incidence of ARF in patients with some blood groups (A & B), with a phenotype of acid erythrocyte phosphatase and HLA loci (HLA-DR4 & HLA-DR2).
3. The presence of a unique gene on the surface of LB (witch induces the formation of monoclonal antibody D8/179) – observed in 90% of patients with ARF and only in 14% general population.
4. ARF has a tendency to occur in some of family members.
Streptococcal infection

Endothelialitis heals ubiquitously, with no residual damage; only heart valves heal with scarring

Damage to overlying endothelium

Widespread collagen matrix involvement

Basement membrane

Streptococcus

M protein

CB3 domains rendered immunogenic

CB3 domain

PARF

Collagen type IV

Antibody directed against collagen (not cross-reactive with M proteins)

Systemic inflammation
Acute Tonsillitis

Immune response

Lymphatic Ganglion

B-Lymphocyte

Antistreptococcic antibody

Blood vessels

Acute rheumatismal carditis

Vegetations

Pericarditis

Aschoff’s nodules
Streptococcal pharyngitis (*Streptococcus β-hemolyticus*)

- Lipoteichoic acid
- Enzymes, toxins
- Activation of complement and phagocytosis

Lymphatic node LB:
Produce of antistreptococcal antibodies

- Activation of LT
- Autoimmunity
- Cross-reaction immune response
- Immune complexes

Immunologic mediated inflammation, autoimmune damage

Carditis:
- Rheumatic valvulitis / sterile vegetations;
- Myocarditis with Aschoff’s nodules;
- Pericarditis;

Rheumatic arthritis

Sydenham’s chorea

Subcutaneous nodules Maynet

Erytema marginatum

Predisposing factors: overcrowding, bad socioeconomic conditions, insufficient sanitation

Person genetically predisposed to ARF
Environmental factors, especially overcrowding

Precipitating event: infection with a strain of group A streptococcus carrying specific virulence factors

Repeated group A streptococcus infections

Susceptible host

Priming of immune response

Molecular mimicry between group A streptococcus antigens and host tissues

Exaggerated T-cell mediated immune response

Genetically-determined host factors

Repeated or ongoing infections possibly driving the valvular inflammatory response

Episodes of recurrent ARF

First episode of ARF

RHD

Carapetis. Lancet 2010;366:155
ARF: histology lesions located in conjunctive tissue of heart, joints, tendons, serouses, arteries, skin, subcutan, lungs, brain, kidney.

**Exudative – degenerative phase** consists in 2 stages:
- Mucoid swelling
- Fibrinoid swelling

**Proliferative phase**
Lymphoid infiltrate occurs, containing also plasmocytes, hystiocytes, fibroblasts and multinuclear giant cells. The granuloma is developing (e.g. Aschoff’s nodules in myocardium)

**Phase of Fibrosing and Cicatrization**
characterizes the inactive phase with residual/sclerotic changes
Pathologic Lesions

- Fibrinoid degeneration of connective tissue, inflammatory edema, inflammatory cell infiltration & proliferation of specific cells resulting in formation of **Ashcoff nodules**, resulting in-
  - **Pancarditis** in the heart
  - **Arthritis** in the joints
  - **Ashcoff nodules** in the subcutaneous tissue
  - Basal ganglia lesions resulting in **chorea**
Acute Rheumatic carditis

• “Aschoft bodies”
• foci of lymphocytes
• occasional plasma cells
• activated macrophages
• Diffuse inflammation
• All three layers of the heart are affected (pancarditis)
• Endocardium: inflammatory foci, fibrinoid necrosis, small vegetations „verrucae”
• Subendocardial lesions: MacCallum patches
• Commonly involved valves are: mitral, aortic, tricuspid
• Thickened and retracted valvular leaflets → permanent deformity
Rheumatic myocarditis

Pathologic forms: acute – Aschoff’s nodules
chronic – Fibrozis

Aschoff’s nodules:
– Small focal perivascular inflammation
– Infiltration with lymphocytes, macrophages and plasmocytes
– Fibrinoid necrosis & collagen degeneration
  +
– Anitschkow’s cells - histiocytes with chromatin accumulation in the nuclei center: “Owl's eye” appearance
– Aschoff’s cells - multinucleated giant cells – result of Anitschkow’s histiocytes confluence
Myocarditis: Aschoff body (fibrinoid necrosis)
Microscopically, acute rheumatic carditis is marked by a peculiar form of granulomatous inflammation - Aschoff nodules.
Histology of Myocardium in Rheumatic Carditis (200X)
Aschoff’s body

Consists of collagen surrounded by T lymphocytes and specialized macrophages (Anitschkow’s cells)

- Large macrophage (Aschoff’s multi-nucleated giant cells and / or Anitschkow's cells (large cytoplasm, ovoid nuclei))
- possible central necrosis
- Aschoff’s multi-nucleated giant cells (rapidly dividing m/p with lots of nuclei but forget to divide the cytoplasm)
Vegetations form along the lines of apposition of the cusps
Rheumatic endocarditis

- **acute phase**: edema of valves, with increased contain of mucopolysaccharides & small friable, soft, reddish vegetations, 1-2 mm, on the commissural part of leaflets, containing thrombocytic masses

- Transition in *chronic rheumatic endocarditis*:
  - organization of vegetations
  - scarification & calcification of valves
  - deformation, confluence of valvular commissures
  - formation of *rheumatic valvulopathy*
Chronic rheumatic carditis

Anatomic changes in mitral (or tricuspid) valve
• Commissural fusion
• Leaflet thickening
• Shortening, fibrosis and thickening of the tendinous cords

• Organization of acute inflammation
• Subsequent deforming fibrosis
Mitral stenosis (fish mouth)
<table>
<thead>
<tr>
<th>Clinical syndromes</th>
<th>Activity</th>
<th>Evolution</th>
<th>Consequences (inactive phase)</th>
<th>Heart failure (NYHA)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rheumocarditis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recurrent Rheumocarditis without /</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>with valvular disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arthritis without / with heart</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>involvement</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chorea without / with heart</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>involvement</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Primary diagnosed valvulopathy</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Secondary</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Erythema marginatum</td>
<td>Maximal (III)</td>
<td>Acute</td>
<td>without valvulopathy with valvulopathy</td>
<td></td>
</tr>
<tr>
<td>Subcutaneous nodules</td>
<td>Moderate (II)</td>
<td>Prolonged</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arthralgia</td>
<td>Minimal (I)</td>
<td>Latent</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abdominal syndrome &amp; other</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>serositis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antecedent streptococcic infection</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical variants</td>
<td>Clinical signs</td>
<td>Consequences</td>
<td>Heart failure (NYHA)</td>
<td></td>
</tr>
<tr>
<td>----------------------------</td>
<td>---------------------------------</td>
<td>-----------------------------------</td>
<td>----------------------</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Primary</td>
<td>Facultative</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acute rheumatic fever</td>
<td>Carditis</td>
<td>Fever</td>
<td>without valvulopathy</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Arthritis</td>
<td>Arthralgia</td>
<td>with valvulopathy</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chorea</td>
<td>Abdominal syndrome</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Erythema marginatum</td>
<td>Serositis</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Subcutaneous nodules</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recurrent rheumatic fever</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Examples of diagnostic formulation

• Acute rheumatic fever, rheumocarditis without valvulopathy, heart failure I NYHA, rheumatic arthritis, erythema marginatum (moderate activity).

• Acute rheumatic fever, rheumocarditis with valvulopathy: mitral insufficiency and stenosis, heart failure III NYHA (low activity).

• Acute rheumatic fever, chorea Sydenham (low activity).

• Chronic rheumatic cardiopathy: mitral stenosis, mitral insufficiency, aortic stenosis, tahi-systolic atrial fibrillation, HF III NYHA.
Clinical Features

Following upper airway infection with GAS:

• Silent period of 2-6 weeks.
• Sudden onset of fever, pallor, malaise, fatigue.
Clinical Features

Characterized by:

• Arthritis.
• Carditis.
• Sydenham’s chorea.
• Erythema marginatum.
• Subcutaneous nodules.

Called “major manifestations” of Jones criteria either because of frequency or specificity.
Clinical Features

Other features:
- Arthralgia.
- Epistaxis.
- Serositis.
- Involvement of lung, kidneys and CNS.
Clinical features

1. Arthritis

- Migratory polyarthritis, involving major joints
- Commonly involved joints - knee, ankle, elbow & wrist
- Occurs in 80% pts, the involved joints are exquisitely tender
- In children below 5 yrs, arthritis usually mild but carditis more prominent
- Arthritis does not progress to chronic disease!
Clinical Features

2. Carditis

- Manifests as **pancarditis** (endocarditis, myocarditis and pericarditis), occurs in 40-50% of cases
- **Carditis is the only manifestation of rheumatic fever that leaves a sequelae & permanent damage to the organ!**
- **Valvulitis occurs in acute phase**
- **Chronic phase - fibrosis, calcification & stenosis of heart valves.**
Rheumatic carditis

**Symptoms:** dyspnea, cardiac palpitations, cough at exercise, cardiac asthma & pulmonary edema (severe cases).

At *physical exam* may be observed orthopnea, acrocyanosis, ascites, peripheral, pedal edema.

**Percussion:** enlarged of relative cardiac dullness, preponderant to the left.
Rheumatic carditis

**Auscultation:**
- Cardiac sounds are attenuated,
- $S_1$ is diminished at the apical zone,
- Systolic apical organic murmur,
- Mid-diastolic murmur (Carey Coombs), formed in mitral valvulitis,
- Diastolic murmur in the Erb’s point (T)
- May be gallop rhythms $S_3$ and $S_4$,
- Arrhythmia, tachycardia, rarely bradycardia.

[Phonocardiograms from normal and abnormal heart sounds]
Carditis & RHD

• The cardiac physical examination could reveal the presence of *pericardial friction* and typically, a *new or changeable cardiac murmur*.

• In young patients, *mitral valvular regurgitation* is the predominant cardiac sign.

• A new *apical systolic murmur* is characteristic.

• *Aortic regurgitation* is less common, but possible.

• Pulmonary and tricuspid valves are rarely involved.

• Mitral stenosis progresses and is seen in young adults.

• *Cardiac bloc* could be observed on ECG.

• The common radiographic sign is *cardiomegaly*. 
Normal mitral valve

Transparent valve leaflet

Long, fine, thin chordae tendineae
Thickened / fused chordae tendinae

Papillary muscle
Rheumatic heart disease.

Abnormal mitral valve. Thick, fused chordae

Vegetations in RHD and IE
Acute rheumatic fever

The cardiac rheumatic damage could cause dramatic complications:

**Acute:**
- Congestive cardiac failure → death
- Valvular vegetations → systemic embolism

**Chronic:**
- Rheumatic valvulopathy
- Chronic cardiac failure
- Arrhythmia
3. Sydenham Chorea

• Occurs in 5-10% of cases
• Mainly in girls of 1-15 yrs age
• May appear even 6 months after the onset of rheumatic fever
• Clinically manifests as clumsiness, deterioration of hand-writing, emotional liability or grimacing of face
Clinical Features

4. Erythema marginatum

• Occurs in <5%.
• Unique, transient lesions of 2-5 cm in size
• Pale center with red irregular margin
• More on trunks & limbs & non-itchy
• Worsens with application of heat
• Often associated with chronic carditis
Erythema marginatum
Clinical Features

5. Subcutaneous nodules

- Occur in 10%
- Painless, pea-sized, palpable nodules
- Mainly over extensor surfaces of joints, spine, scapulae & scalp
- Always associated with severe carditis
Subcutaneous nodule
Clinical features

Other features (Minor features)
• Fever – Low grade
• Arthralgia
• Pallor
• Anorexia
• Loss of weight
Major manifestations of acute rheumatic fever

- Polyarthritits
- Carditis
- Erythema marginatum
- Chorea
Laboratory findings

- High ESR
- Anemia, leukocytosis
- Elevated C-reactive protein
- ASLO titer > 200.
- Throat culture - GA β-hemolytic streptococci
Laboratory findings

- ECG- prolonged PR interval
- Echo - valve edema, mitral regurgitation, LA & LV dilatation, pericardial effusion, decreased contractility
Radiograph of Carditis in Rheumatic Fever

- Manubrium
- Superior vena cava
- Right main bronchus
- Horizontal fissure
- Right atrium
- Inferior vena cava
- Left main bronchus
- Left atrium
- Pulmonary trunk
- Aortic arch
- Oblique fissure
- Oblique fissure
- Gastric bubble
- Liver
- Daphragm
- Left costophrenic angle
Rheumatic carditis

Mitral regurgitation

Aortic regurgitation
Rheumatic carditis

Mitral stenosis; 2D echocardiography

Doppler echocardiography in mitral stenosis
Diagnosis

• Rheumatic fever is mainly a clinical diagnosis
• No single diagnostic sign or specific laboratory test available for diagnosis
• Diagnosis based on Modified Jones Criteria
Jones Criteria (revised 1992) for diagnosis of ARF

Diagnosis requires:

1) 2 major criteria or 1 major & 2 minor

+  

2) Evidence of recent streptococcal infection.

_in case of chorea or certain carditis, the evidence of antecedent GAS infection is not needed._
Jones Criteria (Revised) for Guidance in the Diagnosis of Rheumatic Fever*

<table>
<thead>
<tr>
<th>Major Manifestation</th>
<th>Clinical</th>
<th>Laboratory</th>
<th>Supporting Evidence of Streptococcal Infection</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carditis</td>
<td></td>
<td></td>
<td>Increased Titer of Anti-Streptococcal Antibodies</td>
</tr>
<tr>
<td>Polyarthritis</td>
<td></td>
<td></td>
<td>ASLO (anti-streptolysin O), others</td>
</tr>
<tr>
<td>Chorea</td>
<td></td>
<td></td>
<td>Positive Throat Culture for Group A Streptococcus</td>
</tr>
<tr>
<td>Erythema Marginatum</td>
<td></td>
<td></td>
<td>Recent Scarlet Fever</td>
</tr>
<tr>
<td>Subcutaneous Nodules</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arthralgia</td>
<td>Previous</td>
<td>Acute phase reactants:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>rheumatic fever</td>
<td>- ESR,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>or rheumatic heart disease</td>
<td>- C-reactive protein,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fever</td>
<td>- leukocytosis</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Prolonged P-R interval</td>
<td></td>
</tr>
</tbody>
</table>

*The presence of two major criteria, or of one major and two minor criteria, indicates a high probability of acute rheumatic fever, if supported by evidence of Group A streptococcal infection.

Recommendations of the American Heart Association
<table>
<thead>
<tr>
<th>Diagnostic category</th>
<th>Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary episode of ARF.</td>
<td>2 major criteria or 1 major &amp; 2 minor + evidence antecedent GAS infection.</td>
</tr>
<tr>
<td>Recurrent attack of ARF without valvulopathy.</td>
<td>2 major criteria or 1 major &amp; 2 minor + evidence antecedent GAS infection.</td>
</tr>
<tr>
<td>Recurrent attack of ARF with previously valvulopathy.</td>
<td>2 major criteria or 1 major &amp; 2 minor + evidence antecedent GAS infection.</td>
</tr>
<tr>
<td>Rheumatic Chorea. Insidious installation of RHD.</td>
<td>Other major criteria. Demonstration of precedent GAS infection is not necessary.</td>
</tr>
<tr>
<td>Chronic valvular lesions (patient is first time diagnosed with mitral stenosis or other valvulopathy: mixed mitral and/or aortic).</td>
<td>Does not need other criteria to confirm the diagnosis of RHD.</td>
</tr>
</tbody>
</table>
Exceptions to Jones Criteria

1. Chorea alone, if other causes have been excluded
2. Insidious or late-onset carditis with no other explanation
3. Patients with documented RHD or prior rheumatic fever, one major criterion, or of fever, arthralgia or high CRP suggests recurrence
AHA Scientific Statement

Revision of the Jones Criteria for the Diagnosis of Acute Rheumatic Fever in the Era of Doppler Echocardiography

A Scientific Statement From the American Heart Association

Endorsed by the World Heart Federation

Michael H. Gewitz, MD, FAHA, Co-Chair; Robert S. Baltimore, MD, Co-Chair; Lloyd Y. Tani, MD, FAHA; Craig A. Sable, MD, FAHA; Stanford T. Shulman, MD; Jonathan Carapetis, MBBS; Bo Remenyi, MBBS; Kathryn A. Taubert, PhD, FAHA; Ann F. Bolger, MD, FAHA; Lee Beerman, MD; Bongani M. Mayosi, MBChB; Andrea Beaton, MD; Natesa G. Pandian, MD; Edward L. Kaplan, MD, FAHA; on behalf of the American Heart Association Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young

Circulation. 2015;131:000-000. DOI: 10.1161/CIR.00000000000000205.
Diagnosis of carditis in the era of widely available EchoCG

**Doppler Findings in Rheumatic Valvulitis**

**Pathological mitral regurgitation (all 4 criteria met)**
- Seen in at least 2 views
- Jet length $\geq 2$ cm in at least 1 view
- Peak velocity $> 3$ m/s
- Pansystolic jet in at least 1 envelope

**Pathological aortic regurgitation (all 4 criteria met)**
- Seen in at least 2 views
- Jet length $\geq 1$ cm in at least 1 view
- Peak velocity $> 3$ m/s
- Pan diastolic jet in at least 1 envelope

**Morphological Findings on Echocardiogram in Rheumatic Valvulitis**

**Acute mitral valve changes**
- Annular dilation
- Chordal elongation
- Chordal rupture resulting in flail leaflet with severe mitral regurgitation
- Anterior (or less commonly posterior) leaflet tip prolapse
- Beading/nodularity of leaflet tips

**Chronic mitral valve changes: not seen in acute carditis**
- Leaflet thickening
- Chordal thickening and fusion
- Restricted leaflet motion
- Calcification

**Aortic valve changes in either acute or chronic carditis**
- Irregular or focal leaflet thickening
- Coaptation defect
- Restricted leaflet motion
- Leaflet prolapse
2D & Doppler echocardiography in mitral stenosis
A, B, C – structural; D, E, F – functional.
# Revised Jones Criteria (Gewitz et al., 2015)

**A. For all patients with evidence of preceding group A streptococcal infection (other than chorea)**

<table>
<thead>
<tr>
<th>Diagnosis: initial ARF</th>
<th>2 major or 1 major plus 2 minor manifestations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diagnosis: recurrent ARF</td>
<td>2 major or 1 major and 2 minor or 3 minor</td>
</tr>
</tbody>
</table>

**B. Major criteria**

<table>
<thead>
<tr>
<th>Low-risk populations</th>
<th>Moderate- and high-risk populations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carditis (&lt;sup&gt;b&lt;/sup&gt; (Clinical and/or subclinical))</td>
<td>Carditis (&lt;sup&gt;b&lt;/sup&gt; (Clinical and/or subclinical))</td>
</tr>
<tr>
<td>Arthritis (Polyarthritis only)</td>
<td>Arthritis (Monoarthritis or polyarthritis or polyarthralgia&lt;sup&gt;c&lt;/sup&gt;)</td>
</tr>
<tr>
<td>Chorea</td>
<td>Chorea</td>
</tr>
<tr>
<td>Erytema marginatum</td>
<td>Erytema marginatum</td>
</tr>
<tr>
<td>Subcutaneous nodules</td>
<td>Subcutaneous nodules</td>
</tr>
</tbody>
</table>

**C. Minor criteria**

<table>
<thead>
<tr>
<th>Low-risk populations</th>
<th>Moderate- and high-risk populations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Polymyalgia</td>
<td>Monoarthralgia</td>
</tr>
<tr>
<td>Fever (≥38.5°C)</td>
<td>Fever (≥38°C)</td>
</tr>
<tr>
<td>ESR ≥60 mm/h and/or CRP ≥3 mg/dL&lt;sup&gt;d&lt;/sup&gt;</td>
<td>ESR ≥30 mm/h and/or CRP ≥3 mg/dL&lt;sup&gt;d&lt;/sup&gt;</td>
</tr>
<tr>
<td>Prolonged PR on ECG (for age) (unless carditis is a major criterion)</td>
<td>Prolonged PR on ECG (for age) (unless carditis is a major criterion)</td>
</tr>
</tbody>
</table>
aLow-risk populations are those with ARF incidence $\leq 2$/ per 100 000 school-aged children or all-age rheumatic heart disease prevalence of $\leq 1$/per 1 000 population per year.

bSubclinical carditis is pathological echocardiographic valvulitis.

cPolyarthritis should only be considered as a major manifestation in moderate- to high-risk populations after exclusion of other causes. As in past versions of the criteria, erythema marginatum and subcutaneous nodules are ‘stand-alone’ major criteria. Additionally, joint manifestations can only been considered in either the major or minor categories but not both in the same patient.

dCRP value must be greater than upper limit of normal for the laboratory. Also because ESR may evolve during the course of ARF, peak ESR values should be used.
Diagnosis strategy for ARF: Chorea

Clinical

yes

ARF Diagnosed

yes

EchoCG Doppler Subclinic Carditis

yes

The evidence of precedent GAS infection is not needed
Diagnosis strategy of ARF: Arthritis.

Clinical or subclinical carditis (EchoCG Doppler)

- Arthritis
  - 2 minor criteria or another major criterion
    - ARF Diagnosed
  - No Carditis
    - No criteria
      - No criteria
        - ARF Diagnosed
        - Alternative diagnosis

Require evidence of GAS infection
Diagnosis strategy of ARF: Clinical Carditis

- **EchoCG**
  - EchoCG confirms valvulitis
    - One minor only
    - Probability ARF
      - Repeat EchoCG at 14-21 days
      - Require evidence of GAS infection
  - Another major criterion or 2 minor criteria
    - ARF Diagnosed
    - Require evidence of GAS infection

- **Negative EchoCG**
  - Alternative Diagnosis
Diagnosis strategy of ARF

Subcutaneous nodules or Erythema marginatim

- Another major criterion* or 2 minor criteria
  - ARF Diagnosed

- No major and/or 1 minor criteria
  - Alternative Diagnosis

Require evidence of GAS infection

*subclinical carditis can be considered
<table>
<thead>
<tr>
<th>Arthritis</th>
<th>Carditis</th>
<th>Chorea</th>
</tr>
</thead>
<tbody>
<tr>
<td>Septic arthritis (including gonococcal)</td>
<td>Physiological mitral regurgitation</td>
<td>Drug intoxication</td>
</tr>
<tr>
<td>Connective tissue and other autoimmune diseases such as juvenile idiopathic arthritis</td>
<td>Mitral valve prolapse</td>
<td>Wilson disease</td>
</tr>
<tr>
<td>Viral arthropathy</td>
<td>Myxomatous mitral valve</td>
<td>Tic disorder</td>
</tr>
<tr>
<td>Reactive arthropathy</td>
<td>Fibroelastoma</td>
<td>Choreathetoid cerebral palsy</td>
</tr>
<tr>
<td>Lyme disease</td>
<td>Congenital mitral valve disease</td>
<td>Encephalitis</td>
</tr>
<tr>
<td>Sickle cell anemia</td>
<td>Congenital aortic valve disease</td>
<td>Familial chorea (including Huntington disease)</td>
</tr>
<tr>
<td>Infective endocarditis</td>
<td>Infective endocarditis</td>
<td>Intracranial tumor</td>
</tr>
<tr>
<td>Leukemia or lymphoma</td>
<td>Cardiomyopathy</td>
<td>Lyme disease</td>
</tr>
<tr>
<td>Gout and pseudo gout</td>
<td>Myocarditis, viral or idiopathic</td>
<td>Hormonal</td>
</tr>
<tr>
<td>Poststreptococcal reactive arthritis</td>
<td>Kawasaki disease</td>
<td>Metabolic (eg, Lesch-Nyhan, hyperalaninemia, ataxia telangiectasia)</td>
</tr>
<tr>
<td>Henoch-Schonlein purpura</td>
<td></td>
<td>Antiphospholipid antibody syndrome</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Autoimmune: Systemic lupus erythematosus, systemic vasculitis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sarcoidosis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hyperthyroidism</td>
</tr>
</tbody>
</table>
Medical therapy for acute rheumatic fever involves the following areas:

- Treat group A streptococcal infection regardless of organism detection.
- Steroids and salicylates are useful in the control of pain and inflammation.
- Heart failure may require digitalis, fluid and sodium restriction, diuretics, and oxygen.
- Administer prophylaxis against GABHS infections to patients who have developed ARF. Most authorities suggest that prophylaxis be given for 5 years. For those who have rheumatic carditis, some authorities suggest lifelong prophylaxis.
- Phenobarbital and haloperidol may be helpful in controlling chorea.
Treatment

• **Step I** - primary prevention (eradication of streptococci)
• **Step II** - anti inflammatory treatment (Aspirin, steroids)
• **Step III** - supportive management & management of complications
• **Step IV** - secondary prevention (prevention of recurrent attacks)
### Step I: Primary Prevention of Rheumatic Fever by treating sore throat

<table>
<thead>
<tr>
<th>Antibiotic</th>
<th>Administration</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benzathine benzyl penicillin</td>
<td>Single IM injection</td>
<td>1.2 MU &gt; 30kg, 600 000 U &lt; 30 kg</td>
</tr>
<tr>
<td>Phenoxymerthyl penicillin (Pen VK)</td>
<td>PO for 10 days</td>
<td>250-500mg qds for 10 days, 125mg qds X 10 if &lt;30 kg</td>
</tr>
<tr>
<td>Erythromycin ethylsuccinate</td>
<td>PO for 10 days</td>
<td>Use same dose as above.</td>
</tr>
</tbody>
</table>

Oral penicillin is less efficacious than Penicillin IM
Anaphylaxis is extremely unusual
<table>
<thead>
<tr>
<th>Antibiotic</th>
<th>Group A Streptococcus</th>
<th>% Resistant to Antibiotic</th>
<th>Numbers Tested</th>
</tr>
</thead>
<tbody>
<tr>
<td>Penicillin</td>
<td></td>
<td>0%</td>
<td>5,126</td>
</tr>
<tr>
<td>Erythromycin*</td>
<td></td>
<td>3.9%</td>
<td>8,688</td>
</tr>
</tbody>
</table>

Source: Environmental Sciences and Research Ltd website: www.esr.cri.nz
Step 1 Primary Prevention of Rheumatic Fever by treating sore throat

For patients allergic to penicillin

Narrow-spectrum cephalosporin (cephalexin [Keflex], cefadroxil [formerly Duricef])†

- Varies

Azithromycin (Zithromax)

- 12 mg per kg (maximum, 500 mg) orally once daily for 5 days

Clarithromycin (Biaxin)‡

- 15 mg per kg orally per day, divided into 2 doses (maximum, 250 mg twice daily), for 10 days

Clindamycin (Cleocin)

- 20 mg per kg orally per day (maximum, 1.8 g per day), divided into 3 doses, for 10 days
Algorithm: Guide for sore throat management

Sore Throat

Aim: All GAS pharyngitis in high rheumatic fever risk patients are treated

High Risk for Rheumatic Fever

- Māori or Pacific
- Aged 3-35 years
- Living in crowded circumstances or lower socioeconomic area

If only 1 criterion see green box.

Primary Care or Emergency Departments

Throat swab if follow up possible

Start 10 days of empiric penicillin or amoxicillin or single dose of IM benzathine penicillin

School Sore Throat Clinics

Throat swab

Wait for result before starting antibiotics

If GAS positive:

Start 10 days of antibiotics

Low Risk for Rheumatic Fever

Assess severity of symptoms and occupational risk of spreading GAS.

1. Unwell patients have potential to develop local suppurative complications

2. Throat swabbing and/or antibiotic treatment may not be required for mild symptoms unless the patient is at increased risk of spreading GAS e.g. healthcare and residential care workers, food handlers, school and early childhood teachers and students. Instead consider analgesia.

   *10 days of empiric penicillin or amoxicillin or single dose of IM benzathine penicillin

If GAS positive:

- Consider swabbing all symptomatic household members.
- Consider isolating at home for 24 hours post starting 10 days of antibiotics.
- Swab all household members (symptomatic or not), if:
  - ≥ 3 cases of GAS pharyngitis in household in the last 3 months, or
  - Personal, family, or household history of rheumatic fever
  and promptly treat all GAS positive cases

See Household Sore Throat Management Algorithm.

If GAS negative:

- Stop antibiotics.
Class Summary

• Because of the direct link between ARF and group A beta-streptococcal infection, the first step in treatment is the *eradication of the organism*. 
**Antimicrobials**

**Penicillin G benzathine**
- Interferes with synthesis of cell wall mucopeptide during active multiplication, resulting in bactericidal activity against susceptible bacteria.
- Because of its prolonged blood level, several authors believe this to be the *Drug of Choice*. Others prefer daily injections.

**Penicillin G procaine**
- Long-acting parenteral penicillin (IM only) indicated in the treatment of moderately severe infections caused by penicillin G–sensitive microorganisms.
- Some prefer 10-d therapy.
- Administer by deep IM injection only into the upper outer quadrant of the buttock. In infants and small children, the midlateral aspect of the thigh may be the best site for administration.
Amoxicillin
• Inhibits the biosynthesis of the cell-wall mucoprotein and is effective during the stage of active multiplication. Inadequate concentrations may produce only bacteriostatic effects. Penicillin VK is the oral alternative for the treatment of rheumatic fever.
• Some authors suggest that once-daily amoxicillin is as effective and can be recommended as an alternative because compliance is likely to be better.

Erythromycin
• DOC for patients allergic to penicillin; inhibits RNA-dependent protein synthesis, possibly by stimulating the dissociation of peptidyl tRNA from ribosomes, which inhibits bacterial growth.
• In children, age, weight, and severity of infection determine the proper dosage. When bid dosing is desired, one-half the daily dose may be administered q12h. For more severe infections, the dose may be doubled.
Azithromycin

• Alternate antibiotic for treating GAS pharyngitis in patients allergic to penicillin.
• Acts by binding to 50S ribosomal subunit of susceptible microorganisms and blocks dissociation of peptidyl tRNA from ribosomes, causing RNA-dependent protein synthesis to arrest. Nucleic acid synthesis is not affected.
• Concentrates in phagocytes and fibroblasts as demonstrated by in vitro incubation techniques. In vivo studies suggest that concentration in phagocytes may contribute to drug distribution to inflamed tissues.
• Treats mild-to-moderate microbial infections.
• Plasma concentrations are very low, but tissue concentrations are much higher, giving it value in treating intracellular organisms. Has a long tissue half-life.
### Step II: Anti-inflammatory treatment

| **Arthritis only** | **Aspirin** 75-100 mg/kg/day, give as 4 divided doses for 6 weeks (Attain a blood level 20-30 mg/dl) **NSAIDs.** These agents should be used regularly to achieve a good anti-inflammatory effect. The choice of a specific agent depends on the individual response to treatment. **Diclofenac** (75-150 mg) or **Meloxicam** (7,5-15 mg) or **Nimesulid** (100-200 mg) or **Ibuprofen** (800 – 1600 mg) or **Flurbiprofen** (100 – 200 mg) |
| **Carditis** | **Prednisolone** 2-2.5 mg/kg/day, give as two divided doses for 2 weeks Taper over 2 weeks & while tapering add **Aspirin** 75 mg/kg/day for 2 weeks. Continue **Aspirin** alone 100 mg/kg/day for another 4 weeks |
Step III: Supportive management & management of complications

• Bed rest
• Treatment of congestive cardiac failure:
  - digitalis, diuretics etc.
• Treatment of chorea:
  - diazepam or haloperidol
• Rest to joints & supportive splinting
Step IV: **Secondary Prevention**

Stops sore throat, prevents recurrences of ARF and aids in regression of RHD

<table>
<thead>
<tr>
<th>Antibiotic</th>
<th>Administration</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benzathine benzyl penicillin</td>
<td>Single IM injection <strong>monthly</strong></td>
<td>1.2 MU &gt; 30 kg</td>
</tr>
<tr>
<td></td>
<td></td>
<td>600 000 U &lt; 30 kg</td>
</tr>
<tr>
<td>Phenoxyethyl penicillin (Pen VK)</td>
<td>BD po daily</td>
<td>250-500 mg bd</td>
</tr>
<tr>
<td>Erythromycin ethylsuccinate</td>
<td>BD po daily</td>
<td>Use same dose as above.</td>
</tr>
</tbody>
</table>

Oral penicillin has been shown to be less effective than Penicillin IM

Anaphylaxis is extremely unusual

In high-risk situations, administration every 3 weeks is justified and recommended
## Secondary prevention: Duration

<table>
<thead>
<tr>
<th>Category</th>
<th>Duration of prophylaxis</th>
</tr>
</thead>
<tbody>
<tr>
<td>All persons with ARF with no or mild carditis</td>
<td>Minimum 5 years after most recent episode or till age 21 (whichever is longer)</td>
</tr>
<tr>
<td>All persons with ARF and moderate carditis</td>
<td>Minimum 10 years after most recent episode or till age 35 (whichever is longer)</td>
</tr>
<tr>
<td>All persons with ARF and severe carditis</td>
<td>Minimum 10 years after most recent episode or age 40 and then specialist review to decide the need to continue. Post surgical cases definitely lifelong.</td>
</tr>
</tbody>
</table>
Prognosis

• Rheumatic fever can recur whenever the individual experience new GABH streptococcal infection, if not on prophylactic medicines.
• Good prognosis for older age group & if no carditis during the initial attack.
• Bad prognosis for younger children & those with carditis with valvular lesions.